Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2017-08-28 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned
Regulatory Filings Classification · 95% confidence The document is a press release from Novartis announcing clinical trial results (CANTOS study) regarding the drug ACZ885 and its effect on lung cancer mortality, published in The Lancet and presented at the European Society of Cardiology (ESC) Congress. This type of announcement, detailing key financial/scientific results for a specific period or study outcome, aligns best with an Earnings Release (ER) if it were quarterly results, or more generally, a Regulatory Filing (RNS) if it doesn't fit other specific categories. However, since it is a detailed announcement of scientific/clinical findings, which often accompanies or precedes formal financial filings, and it is not a full report (like 10-K or IR), nor a management discussion (MDA), nor a transcript (CT), it functions as a significant public disclosure. Given the options, and recognizing that this is a major announcement of results that often precedes formal regulatory filings or is released alongside them, it most closely resembles an Earnings Release (ER) in function (announcing key period results/developments) or a general Regulatory Filing (RNS). Since it is focused on scientific data rather than standard quarterly financial performance highlights, RNS is a strong candidate as a general disclosure. However, in many contexts, major clinical trial result announcements are treated similarly to earnings releases as they drive investor sentiment. Given the content is a scientific/clinical breakthrough announcement, and not a standard financial earnings report, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for a significant, non-standard disclosure. If the document were shorter and just pointed to the publication, RPA would apply, but this is the full content of the announcement itself. I will classify it as RNS as it is a broad regulatory/public announcement of material information not covered by other specific codes.
2017-08-28 English
Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
Earnings Release Classification · 95% confidence The document is a press release dated August 27, 2017, announcing the primary data results from the Phase III CANTOS study evaluating the drug ACZ885 for cardiovascular risk reduction. It details clinical trial outcomes, mentions simultaneous publication in NEJM and presentation at the European Society of Cardiology (ESC) Congress, and includes forward-looking statements typical of corporate news releases regarding regulatory submissions. This format—a formal announcement of significant financial/clinical results, often released before or alongside a full regulatory filing—best fits the 'Earnings Release' (ER) category, which covers initial announcements of periodical results or major operational milestones, or potentially 'Regulatory Filings' (RNS) if it were a general announcement. However, since it is a detailed release of study results which often accompanies or precedes quarterly/annual financial reporting periods, and given the structure is that of a news announcement rather than a formal SEC filing like a 10-K or IR, 'ER' (Earnings Release, used broadly for major periodic results announcements) is the most appropriate fit among the options, although 'RNS' is a close secondary candidate if the focus is purely on the announcement mechanism. Given the content is a major data release, ER is selected as it often covers significant operational/clinical milestones that impact future earnings. Q3 2017
2017-08-28 English
Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
Earnings Release Classification · 95% confidence The document is a press release dated August 27, 2017, announcing the primary data results from the Phase III CANTOS study evaluating the drug ACZ885 for cardiovascular risk reduction. It details clinical trial outcomes, mentions simultaneous publication in NEJM and presentation at the European Society of Cardiology (ESC) Congress, and includes forward-looking statements typical of corporate news releases regarding regulatory submissions. This format—a formal announcement of significant financial/clinical results, often released before or alongside a full regulatory filing—best fits the 'Earnings Release' (ER) category, which covers initial announcements of periodical results or major operational milestones, or potentially 'Regulatory Filings' (RNS) if it were a general announcement. However, since it is a detailed release of study results which often accompanies or precedes quarterly/annual financial reporting periods, and given the structure is that of a news announcement rather than a formal SEC filing like a 10-K or IR, 'ER' (Earnings Release, used broadly for major periodic results announcements) is the most appropriate fit among the options, although 'RNS' is a close secondary candidate if the focus is purely on the announcement mechanism. Given the content is a major data release, ER is selected as it often covers significant operational/clinical milestones that impact future earnings. Q3 2017
2017-08-28 English
PRIMARY DOCUMENT
Director's Dealing
2017-08-23 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It references exhibits including a Financial Report for Q2 2017 and an Interim Financial Report. The document length is only 1482 characters, which is quite short and does not contain actual financial statements or substantive financial data itself, but rather appears to be a cover or transmittal document for the interim financial report. According to the MENU VS MEAL RULE, such a short document that references reports but does not contain the reports themselves should be classified as a Regulatory Filing (RNS).
2017-07-18 English
Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
Interim / Quarterly Report Classification · 100% confidence The document is a detailed financial release from Novartis for the second quarter (Q2) and first half (H1) of 2017. It contains comprehensive financial tables, including net sales, operating income, net income, EPS, and free cash flow, along with detailed management commentary on business segments (Innovative Medicines, Sandoz, Alcon) and growth drivers. Because it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q2 2017
2017-07-18 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.